ENDRA Life Sciences is engaged in developing technology in clinical diagnostic ultrasound for patient access to the diagnosis and treatment of various medical conditions. Co.'s Thermo-Acoustic Enhanced Ultrasound (TAEUS) technology uses a pulsed energy source, radio-frequency, to generate ultrasonic waves in tissue. These waves are then detected with ultrasound equipment and used to create images and other forms of data using its proprietary algorithms. Co. is also developing TAEUS for incorporation into new ultrasound systems manufactured by companies such as General Electric Company, acting through its GE Healthcare business unit and the GE Global Research Center. The NDRA stock yearly return is shown above.
The yearly return on the NDRA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NDRA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|